EUVIMEDEUVIMED entdecken
Systematische Übersicht

The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review

Ali Sarabi Asiabar, Mohammad Ali Rezaei, Dariush Jafarzadeh, Soheila Rajaei, Pezhman Atefimanesh, Samira Soleimanpour, Mohammad Hossein Kafaei Meher, Samad Azari

European Journal of Clinical Pharmacology · 2024

DOI: 10.1007/s00228-024-03755-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Ali Sarabi Asiabar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Cost-Benefit Analysis, Obesity, Overweight. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The present study aimed to systematically collect and synthesize available cost-effectiveness studies of semaglutide in patients with obesity or overweight in comparison with other interventions. METHODS: We comprehensively searched multiple electronic databases to identify relevant literature. Studies were selected based on inclusion and exclusion criteria. The quality of studies was appraised using the "Consolidated Health Economic Evaluation Reporting Standards" (CHEERS) tool. This study is conducted and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. RESULTS: Out of a total of 252 items, after review, 32 articles were fully reviewed, and, finally, 7 studies met inclusion and exclusion criteria. The discount rate was in the range of 1.5-3.5%. Studies included showed semaglutide offered more QALYs than anti-obesity drugs but because of higher cost, in some cases, ICER exceeds the willingness to pay threshold. Results show that semaglutide creates higher total cost compared to conventional interventions in patients with class I, II, and III obesities. Results show that in patients with class I obesity (BMI 33) lifestyle intervention (LI), endoscopic sleeve gastroplasty (ESG), Sleeve gastrectomy (SG), and semaglutide create $124,195; $126,732; $139,971; and $370,776, respectively. CONCLUSION: The current systematic review showed that semaglutide provides more QALYs and creates more costs in comparison with phentermine-topiramate, phentermine, and naltrexone-bupropion. Semaglutide may be cost-effective with substantial cost reduction. Semaglutide appears to be cost-effective versus diet and exercise (D&E) and liraglutide but it was not cost-effective versus sleeve gastrectomy, endoscopic sleeve gastroplasty, and gastric bypass.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesCost-Benefit AnalysisObesityOverweightAnti-Obesity AgentsHumansAdolescentAdultQuality-Adjusted Life YearsCost-Effectiveness AnalysisSemaglutide

Stichwörter der Autor:innen

Anti-obesityCost-effectivenessObesityOverweightSemaglutide

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsSemaglutide

Autor:innen und Institutionen

  • Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
  • Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
  • Research Center for Emergency and Disaster Resilience, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran.
  • Health Promotion Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Educational Development Center, Iran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03755-w

Vancouver

Asiabar AS, Rezaei MA, Jafarzadeh D, Rajaei S, Atefimanesh P, Soleimanpour S, et al. The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03755-w

BibTeX
@article{Asiabar2024,
  author = {Asiabar, Ali Sarabi and Rezaei, Mohammad Ali and Jafarzadeh, Dariush and Rajaei, Soheila and Atefimanesh, Pezhman and Soleimanpour, Samira and Meher, Mohammad Hossein Kafaei and Azari, Samad},
  title = {The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review},
  journal = {European Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1007/s00228-024-03755-w}
}
Kostenlos starten →